Ab Initio Biotherapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $12M

Ab Initio Biotherapeutics General Information

Description

Developer of protein engineering platform designed for the discovery of therapeutic antibodies against difficult-to-access cellular targets. The company's platform allows for targeting multi-transmembrane and facilitates antibody generation relevant to a wide array of therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders, enabling doctors to optimize the solubility and stability of drugs.

Contact Information

Website
www.aibio.com
Ownership Status
Acquired/Merged
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 280 Utah Avenue
  • South San Francisco, CA 94080
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ab Initio Biotherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 23-Jul-2019 $12M 000 0000 Completed Generating Revenue
3. Corporate 13-Dec-2016 000 Completed Startup
2. Angel (individual) $2M $2M Completed Startup
1. Accelerator/Incubator 03-Mar-2015 Completed Startup
To view Ab Initio Biotherapeutics’s complete valuation and funding history, request access »

Ab Initio Biotherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of protein engineering platform designed for the discovery of therapeutic antibodies against difficult-to-acce
Biotechnology
South San Francisco, CA
000
000 0000-00-00
000000&0 000

000000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim
0000 000000000
Houston, TX
00 As of 0000
00000
0000000000 00000

000000

t, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et do
0000 000000000
Grand Cayman, Cayman Islands
00000 As of 0000
00.000
00000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ab Initio Biotherapeutics Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
OncoResponse Venture Capital-Backed Houston, TX 00 00000 0000000000 00000
BeiGene Formerly PE-Backed Grand Cayman, Cayman Islands 00000 00.000 00000000000 00.000
Blueprint Medicines Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Sangamo Therapeutics Formerly VC-backed Brisbane, CA 000 00000 000000000 00000
You’re viewing 5 of 20 competitors. Get the full list »

Ab Initio Biotherapeutics Patents

Ab Initio Biotherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220220214-A1 Apj modulators and uses thereof Pending 19-Jun-2019 00000000000
US-9845345-B2 Sirp polypeptide compositions and methods of use Active 18-May-2015 000000000 0
US-10774125-B2 Sirp-gamma polypeptide compositions and methods of use Active 18-May-2015 00000000000 0
US-20200270324-A1 Sirp polypeptide compositions and methods of use Active 18-May-2015 00000000000
US-20160340397-A1 Sirp polypeptide compositions and methods of use Active 18-May-2015 C07K14/55 0
To view Ab Initio Biotherapeutics’s complete patent history, request access »

Ab Initio Biotherapeutics Executive Team (6)

Name Title Board Seat Contact Info
Robert Booth Ph.D Co-Founder & Executive Chairman
You’re viewing 1 of 6 executive team members. Get the full list »

Ab Initio Biotherapeutics Board Members (1)

Name Representing Role Since
Robert Booth Ph.D Self Co-Founder & Executive Chairman 000 0000
To view Ab Initio Biotherapeutics’s complete board members history, request access »

Ab Initio Biotherapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Pfizer (Pharmaceuticals) Corporation Minority 000 0000 000000 0
Polaris Partners Venture Capital Minority 000 0000 000000 0
To view Ab Initio Biotherapeutics’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »